Regenacy Pharma strengthens its Board along with raising $30m Series A financing co-led by Cobro Ventures and Taiwania Capital

– USA, MA –  Regenacy Pharmaceuticals, a clinical-stage biopharmaceutical company developing breakthrough treatments for diabetic and other peripheral neuropathies, today announced the closing of a $30 million Series A financing co-led by Cobro Ventures and Taiwania Capital Management, with participation from 3E Bioventures Capital, Yonjin Capital, VIVA Biotech Holdings, TA YA VENTURE HOLDINGS LIMITED, and other undisclosed private investors.…